NovaBay Pharmaceuticals (NYSE:NBY) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report issued on Monday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Down 2.7 %

Shares of NBY stock opened at $0.71 on Monday. The stock has a 50-day simple moving average of $0.66 and a 200 day simple moving average of $2.31. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $17.40. The stock has a market capitalization of $768,220.00, a P/E ratio of -0.01 and a beta of 0.73.

NovaBay Pharmaceuticals (NYSE:NBY) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The company had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. On average, sell-side analysts anticipate that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current year.

Institutional Investors Weigh In On NovaBay Pharmaceuticals

An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Armistice Capital LLC bought a new position in NovaBay Pharmaceuticals, Inc. (NYSE:NBY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned about 11.01% of NovaBay Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.